The IPO market has attracted the retail category for institutional investors such as mutual funds and, according to a September report, mutual funds have racked up IPO shares of a substantial value. Now that the Street has witnessed some correction due to profit reservation, but overall sentiment looks positive, IPOs will continue to be seen taking advantage of the current momentum.
Within the industry, the pharmaceutical industry is riding the IPO wave with not only listing gains, but also offering extraordinary returns from listing. Now of Rs. 65,000 crore raised through the IPO so far this year, nearly 22% has been accounted for by the health and pharmacy space.
Now, after a lot of the space has already made its way to D Street, a few more in the pipeline that have done their initial formality by filing a DRHP IPO are given below:
1 Wellness Forever Medicare:
This is a company backed by Adar Poonawalla who filed DRHP for Rs. 1500 crore IPO bid. The IPO consists of a new issue of shares up to Rs 400 crore and an offer to sell up to 1.60 crore of shares, according to DRHP. This is the second IPO of a Mumbai-based drugstore chain present in 23 cities of Maharashtra, Goa and Karnataka.
2. Global Health Ltd./ Medanta Hospitals:
The group that operates the hospital under the Medanta brand has filed a first request to sell shares. The initial public offering (IPO) consists of a new issue of shares amounting to Rs 500 crore and a selling offer of up to 4.84 crore of shares, according to the draft red herring prospectus (DRHP).
Under the current regime there are 4 hospitals operating in 4 towns and one is under construction in Patna and the other is planned for Noida.
3. Sahajanand Medical Technologies:
The cardiac stent manufacturing company has requested Rs. IPO of 1,500 crore. The issue includes a new share issue of approximately Rs 410 crore and a sell offer of Rs 1,089 crore. It will also offer a partial exit to investors Morgan Stanley Private Equity Asia and Samara Capital who respectively hold 18.44 % and 36.59% of the company.
4. Veeda Clinical Research Limited:
The clinical research entity Veeda Clinical Research Limited has filed its draft red herring prospectus (DRHP) with the capital markets regulator Securities and Exchange Board of India (Sebi) to raise funds in primary markets.
The issue will consist of an issue of new shares with a value of up to Rs331.60cr and an offer to sell (OFS) of Rs500cr by the promoters and existing shareholders.
5. Healthium Medtech:
The global medical technology company focused primarily on surgical, post-surgical and chronic care has filed for an IPO. The public offering includes a new issue of Rs 390 crore and an offer to sell 3.91 crore of shares by the selling shareholders. It is proposed that the funds raised from the new issue be used to repay debts, investments in subsidiaries, acquisitions and other strategic initiatives and for general corporate purposes.
6. MedPlus health service:
The Hyderabad-based pharmacy retail company filed DRHP for Rs. IPO of 1,639 crore. The IPO will include a new issue of shares valued at Rs 600 crore and an offer to sell (OFS) of shares up to Rs 1,038.7 crore by the promoter and shareholders.
The company’s offerings range from pharmaceutical and wellness products including drugs, vitamins, medical devices and test kits, to FMCG products such as personal and household care products including toiletries, baby care products, soaps, detergents and disinfectants.
7. Initial public offering of Infinion Biopharma:
The company has filed DRHP for the sale of 45 lakh shares of the company.
It is a life sciences company
Infinion Biopharma is an innovation-driven life science company that integrates biophysics and engineering with traditional pharmacology and biochemistry to produce innovative products with high added value in a range of therapeutic areas.
8. Emcure Pharma:
The main pharmaceutical company is expected to launch an IPO for Rs. 4,500-5,000 crore IPO. The initial public offering (IPO) includes a new issue of shares valued at Rs. 1,100 crore and an offer to sell (OFS) of 18,168,356 shares by existing promoters and shareholders, according to the draft red herring prospectus (DRHP).
The company manufactures a wide range of pharmaceutical products in all therapeutic areas.
9. Supriya Life Sciences:
The Mumbai-based drug manufacturing company has filed for an IPO for Rs. 1,200 crore IPO.
According to the prospectus, the IPO consists of a new issue of shares worth Rs 200 crore and an offer to sell (OFS) of shares worth up to Rs 1,000 crore held by its promoter Satish Waman Wagh. The par value of each share is Rs 2.
The company is the leading API manufacturer and supplier with an emphasis on research and development.
10. VLCC Health Care Ltd. :
The wellness company has filed for fundraising via an IPO. The company in 2016 had withdrawn from its IPO due to the demonetization at the time. The initial public offering includes a new issue of Rs 300 crore by the company and an offer to sell 89 22,672 shares by the promoter and investors.
For investing articles, business news and mutual fund advice